Itraconazole to prevent fungal infections in chronic granulomatous disease

New England Journal of Medicine

Volumn 348, Issue 24, 2003, Pages 2416-2422

  Gallin, John I ^a,d   Alling, David W ^b   Malech, Harry L ^a   Wesley, Robert ^b   Koziol, Deloris ^b   Marciano, Beatriz ^a   Eisenstein, Eli M ^a   Turner, Maria L ^c   DeCarlo, Ellen S ^a   Starling, Judith M ^b   Holland, Steven M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; HYDROGEN PEROXIDE; ITRACONAZOLE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; BACTERIAL INFECTION; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYCOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION SENSITIVITY; LIVER DYSFUNCTION; MALE; MYCOSIS; PAECILOMYCES LILACINUS; PHAGOCYTE; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; MYCOSES; PATIENT COMPLIANCE; RARE DISEASES;

EID: 0038242951     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021931     Document Type: Article

References (20)

1. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000;343:1703-14.
2. Winkelstein JA, Marino MC, Johnston KB, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
3. Margolis DH, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990;162:723-6.
4. Weening RS, Kabel P, Pijman P, Roos D. Continuous therapy with trimethoprim-sulfamethoxazole in patients with chronic granulomatous disease. J Pediatr 1983;103:127-30.
5. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509-16.
6. Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi. Am J Med 1981;71:59-66.
7. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-3.
8. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32:Suppl 1:67-87.
9. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-6.
10. Van Cauteren H, Heykants J, De Coster R, Cauwenbergh G. Itraconazole: pharmacologic studies in humans and animals. Rev Infect Dis 1987;9:Suppl 1:S43-S46.
11. Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P. NIH conference: recent advances in chronic granulomatous disease. Ann Intern Med 1983;99:657-74.
12. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 1972;286:808-12.
13. Efton B. Forcing a sequential experiment to be balanced. Biometrika 1971;58:403-17.
14. Myoken Y, Sugata T, Kyo T, Fujihara M, Mikami Y. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. J Periodontol 2002;73:33-8.
15. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998;37:303-8.
16. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-e90.
17. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KB. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34:277-84.
18. Smith DE, Bell J, Johnson M, et al. A randomized, double-blind, placebo-controlled study of itraconazole capsules in the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Med 2001;2:78-83.
19. Lamy T, Bernard M, Courtois A, et al. Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. Leuk Lymphoma 1998;30:163-74.
20. Ahmad S, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-7.